GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vext Science Inc (XCNQ:VEXT) » Definitions » Debt-to-EBITDA

Vext Science (XCNQ:VEXT) Debt-to-EBITDA : -4.45 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vext Science Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vext Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$8.64 Mil. Vext Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$44.23 Mil. Vext Science's annualized EBITDA for the quarter that ended in Mar. 2024 was C$-11.89 Mil. Vext Science's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -4.45.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Vext Science's Debt-to-EBITDA or its related term are showing as below:

XCNQ:VEXT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.22   Med: 1.6   Max: 3.06
Current: 3.06

During the past 7 years, the highest Debt-to-EBITDA Ratio of Vext Science was 3.06. The lowest was 0.22. And the median was 1.60.

XCNQ:VEXT's Debt-to-EBITDA is ranked worse than
64.99% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.68 vs XCNQ:VEXT: 3.06

Vext Science Debt-to-EBITDA Historical Data

The historical data trend for Vext Science's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vext Science Debt-to-EBITDA Chart

Vext Science Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial 1.60 2.08 1.14 2.51 2.30

Vext Science Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.08 4.37 22.49 0.78 -4.45

Competitive Comparison of Vext Science's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vext Science's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vext Science's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vext Science's Debt-to-EBITDA falls into.



Vext Science Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vext Science's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.396 + 43.386) / 22.495
=2.30

Vext Science's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.635 + 44.23) / -11.892
=-4.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Vext Science  (XCNQ:VEXT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Vext Science Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vext Science's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vext Science (XCNQ:VEXT) Business Description

Traded in Other Exchanges
Address
4152 N. 39th Avenue, Phoenix, AZ, USA, 85019
Vext Science Inc provides management, advisory, cultivation, and dispensary services to entities in the medical cannabis field. The company's expertise spans from cultivation through to retail operations. Its revenue sources include management fees, professional services, product sales, equipment leasing and property leasing.
Executives
Caroline Marie-clothilde Williams Director

Vext Science (XCNQ:VEXT) Headlines

No Headlines